Eli Lilly's most recent trend suggests a bullish bias. One trading opportunity on Eli Lilly is a Bull Put Spread using a strike $114.00 short put and a strike $109.00 long put offers a potential 26.26% return on risk over the next 9 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $114.00 by expiration. The full premium credit of $1.04 would be kept by the premium seller. The risk of $3.96 would be incurred if the stock dropped below the $109.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Eli Lilly is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Eli Lilly is bullish.
The RSI indicator is at 55.9 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
Deal-making in the global health-care sector is set to rebound in 2019, law firm says
Tue, 08 Jan 2019 05:36:00 +0000
Deal-making activity in the fast growing health-care sector is expected to rebound in 2019, law firm Baker McKenzie says. The number of mergers and acquisitions will increase by 7 percent in 2019 to $331 billion, marking a recovery from last year's drop of 5 percent, the firm said in a joint report with Oxford Economics. The report comes as Bristol-Myers Squibb and Eli Lilly announced acquisitions this month focused on cancer drugs.
[$$] Eli Lilly to Buy Loxo Oncology in $8 Billion Deal
Tue, 08 Jan 2019 03:48:43 +0000
Eli Lilly & Co. said it is buying Loxo Oncology Inc. for $8 billion in cash, a deal that expands the biopharmaceutical company’s oncology-treatment portfolio and adds to a string of recent deals in the cancer-treatment space. Lilly, based in Indianapolis, will pay $235 a share, a 68% premium to Loxo’s closing price on Friday of $139.87. Shares of Eli Lilly rose 0.4%.
Lilly makes $8 billion bet on drugs for rare cancers with Loxo Oncology buy
Tue, 08 Jan 2019 03:14:48 +0000
The price represents a 68 percent premium to Loxo's Friday share price close, which some Wall Street analysts said was high for a company with only one drug on the market that it shares with a partner. Loxo shares surged 66 percent to $232.65, close to the offer price of $235 per share, and prompted stock price rises for a other small developers of targeted cancer therapies, including Array BioPharma, Blueprint Medicines Corp and Clovis Oncology Inc. Lilly shares rose 0.5 percent to $115.28. The cash deal comes on the heels of Bristol-Myers Squibb Co's agreement last week to buy Celgene Corp for $74 billion in the largest pharmaceutical deal ever, spurring investors' hopes of a new wave of large healthcare acquisitions.
Gilead, Pfizer Execs Suggest Even More Pharma M&A Is on Way
Tue, 08 Jan 2019 01:44:04 +0000
Eli Lilly & Co. said Monday it will acquire Loxo Oncology Inc. for about $8 billion in cash. The announcement came just days after Bristol-Myers Squibb Co. and Celgene Corp. announced a $74 billion cash-and-stock deal, the biggest pharma deal ever. “First and foremost, we’re focused on M&A,” Gilead Sciences Inc. Chief Financial Officer Robin Washington said Monday at the J.P. Morgan Healthcare Conference in San Francisco.
PRESS DIGEST- Financial Times – Jan 8
Tue, 08 Jan 2019 01:14:58 +0000
The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines Daimler speeds up self-driving trucking technology https://on.ft.com/2REup9O …
Also on Market Tamer…
Follow Us on Facebook